Opportunity Information: Apply for RFA DA 10 018
Apply for RFA DA 10 018
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Medications Development for Substance Related Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jan 26, 2010 and posted on Jan 25, 2010.
- Applicants must submit their applications by Apr 29, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $10,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,000,000.00 in funding.
- Eligible applicants include: Private institutions of higher education City or township governments State governments Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Public and State controlled institutions of higher education Small businesses County governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Medications Development for Substance Related Disorders (R01) funding opportunity (RFA-DA-10-018) is a National Institutes of Health program run by the National Institute on Drug Abuse (NIDA) aimed at speeding up the real-world development of medications for substance related disorders (SRDs). The core focus is on translational work, meaning studies that help move promising scientific ideas into practical treatments. NIDA is looking for a wide range of projects, including preclinical research (for example, laboratory and animal studies that establish proof of concept, dosing rationale, safety signals, mechanisms, or candidate selection) and clinical research (such as early human studies that evaluate safety, tolerability, pharmacokinetics, preliminary efficacy, or other steps that position a medication closer to regulatory clearance). The larger end goal is to advance candidates toward, or all the way to, U.S. Food and Drug Administration (FDA) approval for treating SRDs.
This opportunity uses the NIH R01 mechanism, which is a standard research project grant structure commonly used for hypothesis-driven and product-development oriented biomedical research. In practical terms, applicants are expected to propose a coherent research plan with clear milestones that can accelerate medication discovery and development, rather than purely descriptive or basic science work with no line of sight to a therapeutic product. The activity category is listed under Education and Health, and the program is tied to CFDA 93.279 (Drug Abuse and Addiction Research Programs). There is no cost sharing or matching requirement, so applicants are not required to contribute non-federal matching funds as a condition of award.
Funding levels and scale are clearly defined. NIDA anticipated supporting around 10 awards, with an estimated total funding pool of $10,000,000 for the competition. The award ceiling is listed as $1,000,000, indicating that individual projects were expected to stay at or below that maximum level (as described in the announcement’s funding limits). While the notice is from 2010 and is archived, the structure illustrates NIDA’s intent at the time: to make multiple sizable investments in medication-development pipelines that could meaningfully advance treatment options for substance use and related disorders.
Eligibility is broad and includes many organization types across academia, government, nonprofit, and industry. Eligible applicants include public and state-controlled institutions of higher education as well as private institutions of higher education, nonprofit organizations both with and without 501(c)(3) status, and for-profit organizations (including small businesses and other for-profit entities). Government entities at multiple levels are eligible, including city or township governments, county governments, state governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The opportunity also welcomes applications from Native American tribal governments (federally recognized) and other tribal organizations, and it explicitly lists a wide set of additional eligible applicants such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based and community-based organizations, U.S. territories or possessions, regional organizations, and even non-U.S. entities (foreign organizations). Federal agencies are also included among eligible applicants, reflecting an intent to encourage collaboration and participation across sectors and geographies where strong medication development work is occurring.
Key dates in the original posting show the timeline for that specific cycle: it was posted on January 25, 2010 (created January 26, 2010), with an original and current closing date of April 29, 2010, and an archive date of May 30, 2010. The full announcement was hosted through the NIH grants guide, and the contact listed is the NIH Office of Extramural Research (OER) webmaster email for access and technical linking issues.
Frequently Asked Questions (FAQs): Medications Development for Substance Related Disorders (R01) - RFA-DA-10-018
What is this funding opportunity?
The Medications Development for Substance Related Disorders (R01) opportunity (RFA-DA-10-018) is a National Institutes of Health (NIH) program run by the National Institute on Drug Abuse (NIDA). It is focused on speeding up real-world development of medications for substance related disorders (SRDs), with an emphasis on translational work that moves promising science toward practical treatment options.
Which NIH institute is running the program?
The program is administered by the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH).
What does "translational" mean in the context of this program?
In this announcement, "translational" refers to studies designed to move scientific ideas and promising candidates closer to practical treatments. The expectation is that proposed work has a clear pathway toward medication development, rather than being purely descriptive or basic research without a line of sight to a therapeutic product.
What kinds of projects are encouraged?
NIDA indicates interest in a wide range of medication-development projects, including both preclinical and clinical research, as long as the work helps accelerate development of medication candidates for SRDs.
What is included under preclinical research for this opportunity?
Examples of preclinical research specifically mentioned include laboratory and animal studies that establish proof of concept, dosing rationale, safety signals, mechanisms, or candidate selection.
What is included under clinical research for this opportunity?
Examples of clinical research mentioned include early human studies evaluating safety, tolerability, pharmacokinetics, preliminary efficacy, or other steps that position a medication candidate closer to regulatory clearance.
What is the long-term goal of the program?
The broader goal is to advance medication candidates toward, or all the way to, U.S. Food and Drug Administration (FDA) approval for treating substance related disorders.
What grant mechanism does this opportunity use?
This opportunity uses the NIH R01 mechanism, a standard research project grant structure commonly used for hypothesis-driven and product-development oriented biomedical research.
What does NIDA expect an application to include?
Applicants are expected to propose a coherent research plan with clear milestones that can accelerate medication discovery and development. The emphasis is on projects that materially advance a candidate or approach toward practical therapeutic use.
Is this opportunity categorized under a specific activity area?
Yes. The activity category is listed under Education and Health.
What CFDA program is this tied to?
The program is tied to CFDA 93.279 (Drug Abuse and Addiction Research Programs).
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement, meaning applicants are not required to provide non-federal matching funds as a condition of award.
How much funding was available for this competition?
NIDA anticipated an estimated total funding pool of $10,000,000 for this competition.
How many awards were expected?
Approximately 10 awards were anticipated.
What is the maximum award size?
The award ceiling is listed as $1,000,000, meaning individual projects were expected to stay at or below that maximum level as described in the announcement’s funding limits.
Is this opportunity current or archived?
The notice is from 2010 and is archived. The timeline shown applies to that specific funding cycle.
What were the key dates for the original cycle?
The opportunity was posted on January 25, 2010 (created January 26, 2010). The original and current closing date listed was April 29, 2010. The archive date was May 30, 2010.
Who is eligible to apply?
Eligibility is broad and includes a wide range of organization types across academia, government, nonprofit, and industry, including U.S. and non-U.S. entities, as listed in the opportunity description.
Are higher education institutions eligible?
Yes. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations with and without 501(c)(3) status are listed as eligible.
Are for-profit organizations eligible?
Yes. For-profit organizations are eligible, including small businesses and other for-profit entities.
Are local and state government entities eligible?
Yes. Eligible government entities include city or township governments, county governments, state governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are tribal governments and tribal organizations eligible?
Yes. Native American tribal governments (federally recognized) and other tribal organizations are explicitly included as eligible applicants.
Are certain institution types specifically welcomed?
Yes. The opportunity explicitly lists a wide set of additional eligible applicants, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, faith-based and community-based organizations, U.S. territories or possessions, and regional organizations.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The eligibility list includes non-U.S. entities (foreign organizations).
Are federal agencies eligible?
Yes. Federal agencies are included among eligible applicants, reflecting an intent to encourage participation across sectors.
Where was the full announcement hosted?
The full announcement was hosted through the NIH grants guide.
Who is listed as the contact for this opportunity?
The contact listed is the NIH Office of Extramural Research (OER) webmaster email, intended for access and technical linking issues.
Browse more opportunities from the same category: Education Health
Next opportunity: Strategic Agricultural Initiative (SAI) Grant Program FY2010
Previous opportunity: National Outreach and Communications Grant Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 10 018
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 10 018) also looked into and applied for these:
| Funding Opportunity |
|---|
| Deep Sequencing and Analysis of Pharmacogenomic Regions Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01) Apply for RFA DA 10 019 Funding Number: RFA DA 10 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 10 001 Funding Number: RFA RM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R01) Apply for PAS 10 097 Funding Number: PAS 10 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R34) Apply for PAS 10 098 Funding Number: PAS 10 098 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R01) Apply for RFA NR 10 001 Funding Number: RFA NR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21) Apply for RFA NR 10 002 Funding Number: RFA NR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 10 108 Funding Number: PA 10 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition U54) Apply for RFA CA 10 503 Funding Number: RFA CA 10 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R21) Apply for RFA NR 10 007 Funding Number: RFA NR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R01) Apply for RFA NR 10 006 Funding Number: RFA NR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Apply for RFA HL 11 002 Funding Number: RFA HL 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Clinical Trials in Drug Abuse (Collaborative R01) Apply for PAR 10 099 Funding Number: PAR 10 099 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 10 126 Funding Number: PAR 10 126 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (Competitive Revision R01) Apply for RFA NR 10 005 Funding Number: RFA NR 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (R01) Apply for RFA NR 10 004 Funding Number: RFA NR 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R03) Apply for PA 10 131 Funding Number: PA 10 131 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R01) Apply for PA 10 129 Funding Number: PA 10 129 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Aspects of HIV/AIDS (R21) Apply for PA 10 130 Funding Number: PA 10 130 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Medical Education Partnership Initiative (MEPI) (R24) Apply for RFA TW 10 008 Funding Number: RFA TW 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Research Education Program for Laboratory Animal Medicine Veterinarians (R25) Apply for RFA RR 10 002 Funding Number: RFA RR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $224,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 10 018", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.